CSIMarket



Best Performing Stocks In Major Pharmaceutical Preparations Industry During The Previous 90 Days



 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 
 

Shares fell by -1.3% on average, in Major Pharmaceutical Preparations Industry during the previous 90 days.

Here are the best performing stocks in Major Pharmaceutical Preparations Industry.




ETST

$0.24

$0.1700 242.86%
Last 90 Days


ETST

$0.24

$0.1700 242.86%



Earth Science Tech Inc

Earth Science Tech Inc stock increased 242.86% during the previous 90 days.


Earth Science Tech Inc is a biotechnology company focused on developing and marketing innovative hemp cannabinoid-based products. Their business model revolves around research, development, manufacturing, and distribution of high-quality CBD and nutraceuticals for various industries, including the pharmaceutical and nutrition sectors.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 5.570 mill. $ 0.542 mill. - mill. - Y/Y 133,208.25 %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 5.570 mill.


$ 0.542 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y 133,208.25 %


MRQ Y/Y - %



RZLT

$5.48

$3.6700 202.76%
Last 90 Days


RZLT

$5.48

$3.6700 202.76%



Rezolute Inc

Rezolute Inc shares increased 202.76% during the previous 90 days.


Rezolute Inc*s business model involves developing and commercializing innovative therapies, focusing on rare and severe chronic metabolic and orphan diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 278.444 mill. $ - mill. $ -58.211 mill. 51 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 278.444 mill.


$ - mill.


$ -58.211 mill.

Employees Shares Outstanding P/E

-


51 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELYM

$8.5

$5.6750 200.88%
Last 90 Days


ELYM

$8.5

$5.6750 200.88%



Eliem Therapeutics Inc

Eliem Therapeutics Inc shares improved 200.88% during the previous 90 days.


Eliem Therapeutics Inc*s business model revolves around developing and commercializing innovative therapeutic solutions for various medical conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 230.104 mill. $ - mill. $ -39.240 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 230.104 mill.


$ - mill.


$ -39.240 mill.

Employees Shares Outstanding P/E

-


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



TNXP

$1.11

$0.7368 197.43%
Last 90 Days


TNXP

$1.11

$0.7368 197.43%



Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Holding Corp stock increased 197.43% during the previous 90 days.


Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 89.776 mill. $ 10.250 mill. $ -102.616 mill. 81 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 89.776 mill.


$ 10.250 mill.


$ -102.616 mill.

Employees Shares Outstanding P/E

-


81 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MAIA

$3.72

$2.3200 165.71%
Last 90 Days


MAIA

$3.72

$2.3200 165.71%



Maia Biotechnology Inc

Maia Biotechnology Inc stock improved 165.71% during the previous 90 days.


Maia Biotechnology Inc is a biotechnology company that focuses on developing innovative therapies for cancer treatment. Their business model revolves around leveraging advanced genomic technologies to identify novel targets for drug development. By combining their expertise in genomics and drug discovery, they aim to create personalized and targeted therapies to improve patient outcomes in the field of oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 50.874 mill. $ - mill. $ -5.307 mill. 14 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 50.874 mill.


$ - mill.


$ -5.307 mill.

Employees Shares Outstanding P/E

-


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CVSI

$0.0846

$0.0527 165.20%
Last 90 Days


CVSI

$0.0846

$0.0527 165.20%



Cv Sciences Inc

Cv Sciences Inc stock increased 165.20% during the previous 90 days.


Cv Sciences Inc operates through a business model focused on the production and sale of cannabidiol (CBD) based products. The company sources hemp for extraction, processes it into various CBD products, and distributes them through multiple channels, including online sales and retail partnerships. By leveraging the growing demand for CBD, Cv Sciences Inc aims to generate revenue and establish a market presence in the emerging health and wellness industry.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.079 mill. $ 15.578 mill. $ 1.658 mill. 155 mill. 4.73 Y/Y 2.45 %
Market Cap. Revenues TTM Net Income TTM

$ 13.079 mill.


$ 15.578 mill.


$ 1.658 mill.

Employees Shares Outstanding P/E

-


155 mill.


4.73

Revenue Growth Income Growth

MRQ Y/Y 2.45 %


MRQ Y/Y - %



XTLB

$2.15

$1.3000 152.94%
Last 90 Days


XTLB

$2.15

$1.3000 152.94%



Xtl Biopharmaceuticals Ltd

Xtl Biopharmaceuticals Ltd stock improved 152.94% during the previous 90 days.


Xtl Biopharmaceuticals Ltd*s business model revolves around developing and commercializing innovative biopharmaceutical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,171.548 mill. $ - mill. $ 0.000 mill. 545 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,171.548 mill.


$ - mill.


$ 0.000 mill.

Employees Shares Outstanding P/E

-


545 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GERN

$5.09

$2.9900 142.38%
Last 90 Days


GERN

$5.09

$2.9900 142.38%



Geron Corp

Geron Corp shares improved 142.38% during the previous 90 days.


Geron Corp is a biopharmaceutical company that focuses on the discovery and development of therapeutic products for the treatment of cancer and chronic degenerative diseases. Their business model is based on researching and identifying innovative drug candidates, conducting preclinical and clinical trials to evaluate their safety and efficacy, and ultimately partnering with larger pharmaceutical companies for late-stage clinical development and commercialization. Geron Corp aims to leverage their scientific expertise and strategic collaborations to bring novel therapies to market and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,949.697 mill. $ 0.317 mill. $ -174.789 mill. 580 mill. - Y/Y -44.78 %
Market Cap. Revenues TTM Net Income TTM

$ 2,949.697 mill.


$ 0.317 mill.


$ -174.789 mill.

Employees Shares Outstanding P/E

25


580 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -44.78 %


MRQ Y/Y - %



EBS

$6.32

$3.5500 128.16%
Last 90 Days


EBS

$6.32

$3.5500 128.16%



Emergent Biosolutions Inc

Emergent Biosolutions Inc stock improved 128.16% during the previous 90 days.


Emergent Biosolutions Inc*s business model focuses on developing and manufacturing specialty products for the prevention and treatment of public health threats.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 329.904 mill. $ 1,184.600 mill. $ -568.500 mill. 52 mill. - Y/Y 81.95 %
Market Cap. Revenues TTM Net Income TTM

$ 329.904 mill.


$ 1,184.600 mill.


$ -568.500 mill.

Employees Shares Outstanding P/E

2,100


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 81.95 %


MRQ Y/Y - %



STOK

$17.19

$9.5400 124.71%
Last 90 Days


STOK

$17.19

$9.5400 124.71%



Stoke Therapeutics Inc

Stoke Therapeutics Inc stock increased 124.71% during the previous 90 days.


Stoke Therapeutics Inc operates on a therapeutic platform that utilizes antisense oligonucleotides to target genetic diseases. The company focuses on developing treatments for severe genetic epilepsies, genetic conditions related to a haploinsufficiency gene, and other genetic disorders that lack effective therapies. Their business model centers around identifying and developing novel therapies that modulate gene expression to address the underlying cause of these diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 760.933 mill. $ 9.248 mill. $ -103.396 mill. 44 mill. - Y/Y 13.87 %
Market Cap. Revenues TTM Net Income TTM

$ 760.933 mill.


$ 9.248 mill.


$ -103.396 mill.

Employees Shares Outstanding P/E

-


44 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 13.87 %


MRQ Y/Y - %



INSM

$61.65

$33.8800 122.00%
Last 90 Days


INSM

$61.65

$33.8800 122.00%



Insmed Inc

Insmed Inc shares improved 122.00% during the previous 90 days.


Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company*s business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc*s efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9,152.312 mill. $ 319.709 mill. $ -746.894 mill. 148 mill. - Y/Y 22.27 %
Market Cap. Revenues TTM Net Income TTM

$ 9,152.312 mill.


$ 319.709 mill.


$ -746.894 mill.

Employees Shares Outstanding P/E

400


148 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 22.27 %


MRQ Y/Y - %



AVTX

$11.49

$6.2500 119.27%
Last 90 Days


AVTX

$11.49

$6.2500 119.27%



Avalo Therapeutics Inc

Avalo Therapeutics Inc shares improved 119.27% during the previous 90 days.


Avalo Therapeutics Inc is a biotechnology company that focuses on developing novel cancer therapies. Their business model revolves around discovering and advancing targeted therapeutics using their proprietary platform technology. They aim to bring innovative treatments to patients by employing a combination of scientific expertise, strategic collaborations, and clinical development.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.884 mill. $ - mill. $ -142.879 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 9.884 mill.


$ - mill.


$ -142.879 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



LPCN

$7.95

$4.3200 119.01%
Last 90 Days


LPCN

$7.95

$4.3200 119.01%



Lipocine Inc

Lipocine Inc stock went up 119.01% during the previous 90 days.


Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 41.617 mill. $ -2.851 mill. $ -16.352 mill. 5 mill. - Y/Y 164.58 %
Market Cap. Revenues TTM Net Income TTM

$ 41.617 mill.


$ -2.851 mill.


$ -16.352 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 164.58 %


MRQ Y/Y - %



NNVC

$2.45

$1.3200 116.81%
Last 90 Days


NNVC

$2.45

$1.3200 116.81%



Nanoviricides inc

Nanoviricides Inc stock improved 116.81% during the previous 90 days.


Nanoviricides Inc. is a pharmaceutical company that operates on a business model based on the development and commercialization of nanomedicines.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 28.860 mill. $ - mill. $ -9.508 mill. 12 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 28.860 mill.


$ - mill.


$ -9.508 mill.

Employees Shares Outstanding P/E

-


12 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



IBIO

$2.55

$1.3700 116.10%
Last 90 Days


IBIO

$2.55

$1.3700 116.10%



Ibio inc

Ibio Inc stock went up 116.10% during the previous 90 days.


Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 9.468 mill. $ - mill. $ -22.245 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 9.468 mill.


$ - mill.


$ -22.245 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



KTRA

$0.1967

$0.1022 108.15%
Last 90 Days


KTRA

$0.1967

$0.1022 108.15%



Kintara Therapeutics Inc

Kintara Therapeutics Inc stock went up 108.15% during the previous 90 days.


Kintara Therapeutics Inc*s business model revolves around the development and commercialization of innovative therapies for the treatment of various types of cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.338 mill. $ - mill. $ -13.023 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.338 mill.


$ - mill.


$ -13.023 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RNA

$38.36

$18.3400 91.61%
Last 90 Days


RNA

$38.36

$18.3400 91.61%



Avidity Biosciences Inc

Avidity Biosciences Inc stock increased 91.61% during the previous 90 days.


Avidity Biosciences Inc*s business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,345.452 mill. $ 10.870 mill. $ -228.681 mill. 87 mill. - Y/Y 58.67 %
Market Cap. Revenues TTM Net Income TTM

$ 3,345.452 mill.


$ 10.870 mill.


$ -228.681 mill.

Employees Shares Outstanding P/E

-


87 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 58.67 %


MRQ Y/Y - %



COCP

$2.8

$1.3300 90.48%
Last 90 Days


COCP

$2.8

$1.3300 90.48%



Cocrystal Pharma Inc

Cocrystal Pharma Inc stock went up 90.48% during the previous 90 days.


Cocrystal Pharma Inc.*s business model focuses on the development of antiviral therapeutics to address unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 28.487 mill. $ - mill. $ -16.240 mill. 10 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 28.487 mill.


$ - mill.


$ -16.240 mill.

Employees Shares Outstanding P/E

11


10 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RSPI

$0.0019

$0.0009 90.00%
Last 90 Days


RSPI

$0.0019

$0.0009 90.00%



Respirerx Pharmaceuticals Inc

Respirerx Pharmaceuticals Inc stock improved 90.00% during the previous 90 days.


Respirerx Pharmaceuticals Inc is a pharmaceutical company that focuses on developing and commercializing therapeutics for the treatment of respiratory diseases. Their business model centers around research, development, and marketing of innovative respiratory drugs to improve patient outcomes and address unmet medical needs in this field.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.320 mill. $ - mill. $ -3.403 mill. 168 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 0.320 mill.


$ - mill.


$ -3.403 mill.

Employees Shares Outstanding P/E

-


168 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELTX

$8.49

$4.0200 89.93%
Last 90 Days


ELTX

$8.49

$4.0200 89.93%



Elicio Therapeutics Inc

Elicio Therapeutics Inc stock increased 89.93% during the previous 90 days.


Elicio Therapeutics Inc is a biotechnology company that focuses on developing novel immunotherapies for treating cancer and other diseases. Their business model involves leveraging proprietary technology platforms to design and manufacture therapeutic vaccines and immune modulators, aiming to provide targeted and personalized treatment options.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 87.226 mill. $ - mill. $ -42.485 mill. 10 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 87.226 mill.


$ - mill.


$ -42.485 mill.

Employees Shares Outstanding P/E

-


10 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VRCA

$8.58

$3.7200 76.54%
Last 90 Days


VRCA

$8.58

$3.7200 76.54%



Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc stock increased 76.54% during the previous 90 days.


Verrica Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing medical solutions for dermatological conditions. Their business model revolves around identifying unmet needs in the dermatology market, conducting rigorous clinical research to develop novel therapies, and efficiently bringing these treatments to market through strategic partnerships and collaborations. Verrica Pharmaceuticals aims to enhance patient outcomes by addressing specific dermatological conditions with innovative solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 395.314 mill. $ 3.204 mill. $ -48.313 mill. 46 mill. - Y/Y -64.94 %
Market Cap. Revenues TTM Net Income TTM

$ 395.314 mill.


$ 3.204 mill.


$ -48.313 mill.

Employees Shares Outstanding P/E

-


46 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -64.94 %


MRQ Y/Y - %



SMMT

$8.25

$3.5300 74.79%
Last 90 Days


SMMT

$8.25

$3.5300 74.79%



Summit Therapeutics Inc

Summit Therapeutics Inc stock increased 74.79% during the previous 90 days.


Summit Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of rare diseases. The company employs a research-driven business model, leveraging its proprietary technologies and expertise to identify and develop novel drugs targeting specific genetic mutations associated with these rare diseases. Summit Therapeutics Inc aims to bring its drug candidates through preclinical and clinical development stages and ultimately secure regulatory approval and commercialize them to benefit patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,789.728 mill. $ - mill. $ -116.025 mill. 702 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,789.728 mill.


$ - mill.


$ -116.025 mill.

Employees Shares Outstanding P/E

70


702 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CNTX

$2

$0.8500 73.91%
Last 90 Days


CNTX

$2

$0.8500 73.91%



Context Therapeutics Inc

Context Therapeutics Inc stock improved 73.91% during the previous 90 days.


Context Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative cancer therapies. Their business model centers around the discovery and development of novel drugs that specifically target and inhibit the growth of hormone-driven cancers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 31.932 mill. $ - mill. $ -21.324 mill. 16 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 31.932 mill.


$ - mill.


$ -21.324 mill.

Employees Shares Outstanding P/E

-


16 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELDN

$2.96

$1.2400 72.09%
Last 90 Days


ELDN

$2.96

$1.2400 72.09%



Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc stock increased 72.09% during the previous 90 days.


Eledon Pharmaceuticals Inc is a pharmaceutical company that operates on a research and development model, focusing on the discovery and development of innovative drugs in various therapeutic areas. They aim to bring new drugs to market by conducting extensive research, clinical trials, and partnering with other pharmaceutical companies for manufacturing and distribution.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 88.724 mill. $ - mill. $ -89.084 mill. 30 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 88.724 mill.


$ - mill.


$ -89.084 mill.

Employees Shares Outstanding P/E

-


30 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DERM

$5.94

$2.4700 71.18%
Last 90 Days


DERM

$5.94

$2.4700 71.18%



Journey Medical Corporation

Journey Medical Corporation shares increased 71.18% during the previous 90 days.


Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 117.359 mill. $ 79.998 mill. $ -4.159 mill. 20 mill. - Y/Y 6.69 %
Market Cap. Revenues TTM Net Income TTM

$ 117.359 mill.


$ 79.998 mill.


$ -4.159 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 6.69 %


MRQ Y/Y - %



RNAZ

$1.23

$0.5000 68.49%
Last 90 Days


RNAZ

$1.23

$0.5000 68.49%



Transcode Therapeutics Inc

Transcode Therapeutics Inc stock increased 68.49% during the previous 90 days.


Transcode Therapeutics Inc*s business model revolves around developing innovative RNA-based therapies to treat a wide range of diseases. By leveraging their expertise in mRNA biology and proprietary drug delivery technology, they aim to create transformative treatments with optimized safety and efficacy profiles.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.325 mill. $ - mill. $ -17.056 mill. 5 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.325 mill.


$ - mill.


$ -17.056 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CALT

$38.9

$15.7700 68.18%
Last 90 Days


CALT

$38.9

$15.7700 68.18%



Calliditas Therapeutics Ab

Calliditas Therapeutics Ab stock improved 68.18% during the previous 90 days.


Calliditas Therapeutics Ab*s business model is focused on developing and commercializing innovative pharmaceutical products to address unmet medical needs in niche markets.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,087.843 mill. $ 129.241 mill. $ -50.115 mill. 54 mill. - Y/Y 49.74 %
Market Cap. Revenues TTM Net Income TTM

$ 2,087.843 mill.


$ 129.241 mill.


$ -50.115 mill.

Employees Shares Outstanding P/E

60


54 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 49.74 %


MRQ Y/Y - %



RGLS

$2.365

$0.9450 66.55%
Last 90 Days


RGLS

$2.365

$0.9450 66.55%



Regulus Therapeutics Inc

Regulus Therapeutics Inc shares improved 66.55% during the previous 90 days.


Regulus Therapeutics Inc*s business model focuses on developing and commercializing RNA-targeted therapeutics.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 67.986 mill. $ - mill. $ -30.445 mill. 29 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 67.986 mill.


$ - mill.


$ -30.445 mill.

Employees Shares Outstanding P/E

50


29 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



HROW

$18.25

$6.8600 60.23%
Last 90 Days


HROW

$18.25

$6.8600 60.23%



Harrow Inc

Harrow Inc shares improved 60.23% during the previous 90 days.


Harrow Health Inc*s business model focuses on developing and commercializing innovative healthcare products and solutions, with a strong emphasis on specialty pharmaceuticals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 647.321 mill. $ 137.484 mill. $ -31.333 mill. 35 mill. - Y/Y 30.38 %
Market Cap. Revenues TTM Net Income TTM

$ 647.321 mill.


$ 137.484 mill.


$ -31.333 mill.

Employees Shares Outstanding P/E

257


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 30.38 %


MRQ Y/Y - %



DRRX

$1.56

$0.5800 59.18%
Last 90 Days


DRRX

$1.56

$0.5800 59.18%



Durect Corp

Durect Corp shares went up 59.18% during the previous 90 days.


Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 42.917 mill. $ 9.194 mill. $ -36.652 mill. 28 mill. - Y/Y -85.44 %
Market Cap. Revenues TTM Net Income TTM

$ 42.917 mill.


$ 9.194 mill.


$ -36.652 mill.

Employees Shares Outstanding P/E

-


28 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -85.44 %


MRQ Y/Y - %



SIGA

$7.88

$2.8900 57.92%
Last 90 Days


SIGA

$7.88

$2.8900 57.92%



Siga Technologies Inc

Siga Technologies Inc stock went up 57.92% during the previous 90 days.


Siga Technologies Inc is a biotechnology company that focuses on the development and commercialization of pharmaceutical products. Their business model revolves around conducting research and development to create innovative therapies for diseases with unmet medical needs. They aim to generate revenue through the sale of their products and securing partnerships and collaborations with other pharmaceutical companies.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 563.916 mill. $ 157.024 mill. $ 79.264 mill. 72 mill. 7.12 Y/Y 205.54 %
Market Cap. Revenues TTM Net Income TTM

$ 563.916 mill.


$ 157.024 mill.


$ 79.264 mill.

Employees Shares Outstanding P/E

60


72 mill.


7.12

Revenue Growth Income Growth

MRQ Y/Y 205.54 %


MRQ Y/Y - %



TLSA

$0.8161

$0.2974 57.34%
Last 90 Days


TLSA

$0.8161

$0.2974 57.34%



Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd stock increased 57.34% during the previous 90 days.


Tiziana Life Sciences Ltd*s business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 84.927 mill. $ - mill. $ -17.691 mill. 104 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 84.927 mill.


$ - mill.


$ -17.691 mill.

Employees Shares Outstanding P/E

-


104 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VNDA

$5.92

$2.1000 54.97%
Last 90 Days


VNDA

$5.92

$2.1000 54.97%



Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc stock went up 54.97% during the previous 90 days.


Vanda Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of innovative therapies for central nervous system disorders. Their business model revolves around conducting research and development activities to identify potential drug candidates, securing intellectual property rights, and seeking regulatory approvals for the commercialization of their products. Through partnerships and collaborations, they aim to bring their novel therapies to market and improve the lives of patients suffering from neurological disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 341.945 mill. $ 177.604 mill. $ -4.889 mill. 58 mill. - Y/Y -24.06 %
Market Cap. Revenues TTM Net Income TTM

$ 341.945 mill.


$ 177.604 mill.


$ -4.889 mill.

Employees Shares Outstanding P/E

500


58 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -24.06 %


MRQ Y/Y - %



AGIO

$47.97

$16.6000 52.92%
Last 90 Days


AGIO

$47.97

$16.6000 52.92%



Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc shares increased 52.92% during the previous 90 days.


Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,704.715 mill. $ 29.403 mill. $ -352.619 mill. 56 mill. - Y/Y 46.00 %
Market Cap. Revenues TTM Net Income TTM

$ 2,704.715 mill.


$ 29.403 mill.


$ -352.619 mill.

Employees Shares Outstanding P/E

-


56 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 46.00 %


MRQ Y/Y - %



BNTC

$7.47

$2.5400 51.52%
Last 90 Days


BNTC

$7.47

$2.5400 51.52%



Benitec Biopharma Inc

Benitec Biopharma Inc stock increased 51.52% during the previous 90 days.


Benitec Biopharma Inc is a biotechnology company that focuses on developing and commercializing gene therapy products. They utilize their proprietary RNA interference technology to target and silence disease-causing genes, ultimately aiming to provide effective treatment options for various genetic diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 19.544 mill. $ - mill. $ -21.692 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 19.544 mill.


$ - mill.


$ -21.692 mill.

Employees Shares Outstanding P/E

-


3 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GHRS

$12.34

$4.1600 50.86%
Last 90 Days


GHRS

$12.34

$4.1600 50.86%



Gh Research Plc

Gh Research Plc shares improved 50.86% during the previous 90 days.


Gh Research Plc*s business model revolves around conducting research and development activities in various sectors, likely focused on a specific industry or area of expertise. They may generate revenue through partnerships, collaborations, licensing, or selling their research findings, products, or services to organizations within their targeted market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 645.799 mill. $ - mill. $ -35.587 mill. 52 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 645.799 mill.


$ - mill.


$ -35.587 mill.

Employees Shares Outstanding P/E

-


52 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RGBP

$1.18

$0.3929 49.92%
Last 90 Days


RGBP

$1.18

$0.3929 49.92%



Regen Biopharma Inc

Regen Biopharma Inc shares increased 49.92% during the previous 90 days.


Regen Biopharma Inc is a biotechnology company that focuses on developing innovative treatments for diseases like cancer and autoimmune disorders. Their business model revolves around conducting research and development activities to create novel therapeutics and licensing or partnering with larger pharmaceutical companies for further development and commercialization. By leveraging their scientific expertise and strategic collaborations, Regen Biopharma aims to bring cutting-edge medical solutions to the market and improve patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.650 mill. $ 0.127 mill. $ -0.842 mill. 4 mill. 406.90 Y/Y 0.00 %
Market Cap. Revenues TTM Net Income TTM

$ 4.650 mill.


$ 0.127 mill.


$ -0.842 mill.

Employees Shares Outstanding P/E

3


4 mill.


406.90

Revenue Growth Income Growth

MRQ Y/Y 0.00 %


MRQ Y/Y - %



AKTX

$3.3

$1.0800 48.65%
Last 90 Days


AKTX

$3.3

$1.0800 48.65%



Akari Therapeutics Plc

Akari Therapeutics Plc shares increased 48.65% during the previous 90 days.


Akari Therapeutics Plc is a biopharmaceutical company that develops and commercializes treatments for autoimmune and inflammatory diseases. Their business model revolves around conducting research, clinical trials, and obtaining regulatory approvals for their product candidates. They aim to provide innovative therapies to patients and generate revenue through the sale and licensing of their products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,030.171 mill. $ - mill. $ -17.748 mill. 312 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,030.171 mill.


$ - mill.


$ -17.748 mill.

Employees Shares Outstanding P/E

15


312 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELVN

$22.75

$7.3500 47.73%
Last 90 Days


ELVN

$22.75

$7.3500 47.73%



Enliven Therapeutics Inc

Enliven Therapeutics Inc shares improved 47.73% during the previous 90 days.


Enliven Therapeutics Inc*s business model focuses on developing and providing effective therapeutic solutions that enhance patient wellness and quality of life.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 933.452 mill. $ - mill. $ -20.029 mill. 41 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 933.452 mill.


$ - mill.


$ -20.029 mill.

Employees Shares Outstanding P/E

-


41 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CNTB

$1.77

$0.5698 47.48%
Last 90 Days


CNTB

$1.77

$0.5698 47.48%



Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited shares increased 47.48% during the previous 90 days.


Connect Biopharma Holdings Limited is a biotechnology company that develops novel therapies for inflammatory diseases by targeting the immune system. Their business model includes research and development of innovative drugs, clinical trials, and partnerships with pharmaceutical companies for commercialization.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 97.519 mill. $ - mill. $ -59.503 mill. 55 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 97.519 mill.


$ - mill.


$ -59.503 mill.

Employees Shares Outstanding P/E

-


55 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %




 1 Day   Week  Current Month of June  30 Days 
Current Quarter Q2 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com